

Addressing child health inequity through case management of under-five malaria in Nigeria: A model-based extended cost-effectiveness analysis

Rishav Raj Dasgupta^{1,2}, Wenhui Mao², Osondu Ogbuoji^{2,3}

¹ Duke University, Trinity College of Arts and Sciences, Durham, North Carolina, USA

² Center for Policy Impact in Global Health at Duke Global Health Institute, Durham, North Carolina, USA

³ Duke Margolis Center for Health Policy, Durham, North Carolina, USA

Corresponding authors: Osondu Ogbuoji
osondu.ogbuoji@duke.edu
310 Trent Drive
Durham, NC, 27710

Rishav Raj Dasgupta
rishavraj.dasgupta@duke.edu
310 Trent Drive
Durham, NC, 27710

1 Abstract

2 **Background:** Under-five malaria in Nigeria remains one of the biggest threats to global
3 child health, accounting for 95,000 annual child deaths. Despite having the highest GDP in Africa,
4 Nigeria's current health financing system has not succeeded in reducing high out-of-pocket
5 medical expenditure, which discourages care-seeking and use of effective antimalarials in the
6 poorest households. Resultingly, Nigeria has some of the worst indicators of child health equity
7 among low and middle-income countries, stressing the need to evaluate how the benefits of health
8 interventions are distributed across socioeconomic lines.

9 **Methods:** We developed a decision tree model for case management of under-five malaria
10 in Nigeria and conducted an extended cost-effectiveness analysis of subsidies covering the direct
11 and indirect costs of treatment. We estimated the number of under-five malaria deaths averted,
12 out-of-pocket (OOP) expenditure averted, cases of catastrophic health expenditure (CHE) averted,
13 and cost of implementation.

14 **Finding:** Fully subsidizing direct medical costs plus a voucher system to cover non-
15 medical and indirect costs with pro-poor increase in treatment coverage would annually avert over
16 19,000 under-five deaths, US\$205.2 million in OOP spending, and 8,600 cases of CHE. Per US\$1
17 million invested, this corresponds to 76 under-five deaths averted, 34 cases of CHE averted, and
18 over US\$800,000 in OOP expenditure averted. Due to low current treatment coverage and high
19 disease burden, the health and financial-risk protection benefits would be pro-poor, with the
20 poorest 40% of Nigerians accounting for 72% of all deaths averted, 55% of all OOP expenditure
21 averted, and 74% of all cases of CHE averted. Targeted subsidies to the poor would see
22 significantly greater health and economic benefits per US\$1 million invested than broad, non-
23 targeted interventions.

24 **Conclusion:** Subsidizing case management of under-five malaria for the poorest and most
25 vulnerable children would significantly reduce illness-related impoverishment and child mortality
26 in Nigeria while preserving limited financial resources.

27

28

29

30

31 INTRODUCTION

32 Despite significant progress in global malaria control over the last two decades, malaria
33 remains one of the leading causes of morbidity and mortality in children under the age of five, who
34 account for two-thirds of the global malaria burden.[1-2] Recent trends also indicate that progress
35 in malaria control is slowing in the highest burden countries.[3] 25% of the global malaria burden
36 is attributable to Nigeria, where malaria annually accounts for an estimated 60% of outpatient
37 hospital visits, 50 million cases, and 100,000 deaths.[4-6] The most vulnerable Nigerians are
38 under-five children, who experience an average of 2-4 episodes of malaria per year and account
39 for as much as 90% of national malaria mortality.[7,8] Moreover, malaria is a leading cause of
40 child death in Nigeria, accounting for as much as 36% of under-five mortality.[9,10]

41 While prompt and effective treatment of malaria has good clinical outcomes in under-five
42 children, cases where treatment is absent, delayed, or ineffective can become severe and lead to
43 life-threatening complications.[7] Nigeria's high under-five malaria mortality is largely
44 attributable to a health financing system that leaves many individuals uninsured, resulting in high
45 out-of-pocket (OOP) medical expenditure that discourages care-seeking behavior, especially
46 among the poor (**Box 1**).[11] Nigeria has one of the lowest rates of care-seeking for suspected
47 cases of under-five malaria in the world, with just under 20% of all under-fives with fever being
48 brought to health facilities for clinical consultation and parasitological testing.[1]

49 Even when care is sought, the most effective malaria treatments are prohibitively costly
50 and used by few Nigerians.[12,13] Artemisinin-based combination therapy (ACT), the WHO-
51 recommended first line of treatment for uncomplicated malaria, is 98% effective in producing the
52 adequate parasitological and clinical response (APCR) necessary for a child to be cured but is up
53 to twenty times more costly than significantly less effective monotherapies such as chloroquine

54 and sulphadoxine-pyrimethamine.[14,15] On account of high cost to individuals, ACTs are used
55 to treat only 40% of under-five malaria cases in Nigeria.[16] Financial barriers especially hurt the
56 poorest and most vulnerable Nigerians, who use ACT at about half the rate of the richest.[16]

57

58 **Box 1: The financial landscape of malaria treatment in Nigeria**

59 In observance of the United Nations Millennium Development Goals (MDGs) for 2000-2015, which
60 aimed in part to eradicate poverty and reduce child mortality, Nigeria's National Health Insurance Scheme
61 piloted the Free Maternal and Child Health Program (FMCHP) in 2009.[17,18] Among other services, the
62 FMCHP provided free malaria treatment to under-five children brought to public health facilities in 12 out
63 of 36 states.[18,19] Introduction of the FMCHP coincided with national reductions in child mortality,
64 indicating potential efficacy of the program.[18] However, the FMCHP ended in 2015 with the conclusion
65 of the MDGs, as states were unable to sustain necessary funding.[18] As a result, most Nigerian's currently
66 pay for malaria treatment out of pocket (OOP).[10]

67 The OOP cost of treating under-five malaria accounts for nearly half of all household medical
68 expense in Nigeria, significantly contributing to catastrophic health expenditure (CHE) in the poorest
69 households.[20] Generally defined as medical expenditure exceeding 10% of annual income, CHE not only
70 leaves individuals unable to pay for future essential health services but often leads to cycles of
71 poverty.[21,22] Globally, CHE pushes nearly 100 million people into poverty per year, exacerbating child
72 health inequalities. Offering financial risk protection, or protection against illness-related impoverishment
73 resulting from CHE, will be essential to make progress toward several of the WHO's Sustainable
74 Development Goals (SDGs) for 2016-2030.[23]

75 To that end, scaling up programs like the FMCHP for the provision of effective malaria treatment
could incentivize care-seeking behavior and increase service use of the most effective therapies, which may
have a positive, pro-poor impact on child health in Nigeria.[19,23,24] Such an intervention would contribute
progress toward several SDGs, namely SDG 1 (reducing poverty), SDG 3 (ensuring good health and well-
being at all ages), and SDG 10 (reducing inequality within societies).[1,24] Financing under-five malaria
treatment through government subsidies would also offer protection against a major source of CHE in
Nigeria, which will help achieve SDG target 3.8: achieving Universal Health Coverage (UHC) that ensures
access to essential health-care services and access to safe, effective, quality and affordable essential
medicines for all.[24,25]

76 Prior studies of countries in Sub-Saharan African have demonstrated that appropriate
77 diagnosis and treatment are cost-effective interventions for case management of under-five
78 malaria, but there are knowledge gaps regarding the cost-effectiveness of such interventions in
79 Nigeria in particular, as well as how equitable such interventions would be.[26] Equity
80 consideration in evidence-informed policymaking will be crucial to improving child health
81 outcomes in Nigeria—with an exceptionally high under-five mortality rate amongst its poorest
82 children (14% vs. 5% for the poorest and richest fifth, respectively), Nigeria has some of the worst
83 examples of child health inequity in the world.[27,28,29]

84 This study estimates the potential health and economic benefits of publicly financing case
85 management of under-five malaria in Nigeria through the provision of government subsidies.
86 Particularly, we apply extended cost effectiveness analysis (ECEA) to estimate intervention
87 benefits across different socioeconomic groups. To account for constraints in government health
88 budgets, we investigate the effects of multiple financing strategies that offer varying levels of
89 coverage.[30] ECEA is an analytical technique that assesses health interventions across two main
90 dimensions: health gains and financial risk protection afforded.[31] Moreover, ECEA
91 disaggregates the effects of interventions across population strata of interest, allowing
92 policymakers to identify which subgroups within a broader target population would benefit most
93 from an intervention.[31] This study adds new value to existing cost-effectiveness research by for
94 the first time investigating how the health and economic benefits of publicly financing case
95 management of under-five malaria would be distributed across socioeconomic lines in Nigeria,
96 with the goal of informing policymakers in creating targeted, cost-effective interventions that help
97 the most vulnerable people while preserving limited financial resources.[32]

98

99 **METHODS**

100 We conducted an extended cost-effectiveness analysis (ECEA) using a decision tree model
101 created with TreeAge Pro Healthcare software, Version 2020 R2. Using demographic and
102 epidemiological data from published literature and unpublished costing data as parameters, we
103 quantified the health and economic effects of three different intervention scenarios over a year of
104 implementation, disaggregated across five wealth quintiles (Q1-Q5 in ascending order of wealth
105 index). The intervention outcomes estimated were the number of under-five deaths averted, OOP
106 expenditure averted, cases of catastrophic health expenditure (CHE) averted, and the cost of
107 implementation.

108 **Patient and Public Involvement Statement**

109 Patients and the public were not involved in any way in this study.

110 **Interventions**

111 Case management of an episode of under-five malaria incurs direct medical costs
112 (consultation, appropriate diagnosis, medical supplies, malaria drugs, other drugs), direct non-
113 medical costs (food on the way to the health facility, transportation, other non-medical supplies
114 and services), and indirect costs (income forgone in productive time lost to caring for a sick
115 child).[33,34,35] In Nigeria, non-medical and indirect costs often represent a high proportion of
116 total expense associated with case management, especially for severe cases that require inpatient
117 hospitalization and significant time spent away from work for caregiving.[19,36]

118 While the FMCHP subsidized the direct medical costs of treatment, off-setting non-
119 medical and indirect costs will more effectively mitigate the economic burden of treating under-
120 five malaria and could further incentivize service use.[19] To consider varying levels of financing
121 capacity, three intervention scenarios were modeled: (1) a 50% subsidy of direct medical costs

122 (50% DMC), (2) a full subsidy of direct medical costs (full DMC), and (3) a full subsidy of direct
123 medical costs in addition to compensating individuals for non-medical and indirect costs through
124 a voucher system (full DMC + NMC + IC). The cost of implementation was estimated from the
125 government perspective.

126 In general, greater subsidies incentivize better care-seeking behavior. Therefore, the model
127 assumes a higher increase in treatment coverage for the interventions that cover a greater
128 proportion of total costs. For example, a full DMC + NMC + IC subsidy is expected to result in
129 the most substantial increase in care-seeking behavior, as it would essentially pay individuals for
130 their lost productive time.[37] The model also assumes pro-poor increase in treatment coverage in
131 which poorer quintiles have higher hypothetical increase in treatment coverage than wealthier
132 quintiles. This assumption is based on findings that indicate FMCHP clinics may have been
133 serviced more by poorer and more disease-burdened wealth groups.[18]

134 For the 50% DMC subsidy, we respectively modeled a 2.5, 2, 1.5, 1, and 0.5 percentage
135 point increase in treatment coverage per quintile; for the full DMC subsidy, we respectively
136 modeled a 5, 4, 3, 2, and 1 percentage point increase in treatment coverage per quintile; for the full
137 DMC + NMC + IC subsidy, we respectively modeled a 10, 8, 6, 4, and 2 percent percentage point
138 increase in treatment coverage per quintile.

139 **Model parameters**

140 Model inputs were disaggregated by wealth quintile (**Table 1**). The 2018 Nigeria
141 Demographic and Health Survey (DHS) makes certain demographic and epidemiological
142 parameters available on a per quintile basis, such as malaria prevalence, treatment-seeking
143 behavior, and usage of ACTs.[16] However, reviewing the literature yielded few other model
144 inputs disaggregated by wealth index. Therefore, several calculations were made based on

145 empirical evidence to estimate certain non-empirical indices per wealth quintile, such as indirect
 146 costs, adherence to ACTs, and cases of under-five malaria. The calculations for estimating select
 147 model parameters by quintile are described in detail in the Supporting Information Section I.
 148 Parameters were calibrated such that the model accurately estimated the current number of annual
 149 under-five malaria deaths in a base case, non-intervention scenario.

150 **Table 1. Summary of model parameters**

| | Parameter | Value (Q1-Q5) | References and Notes |
|---------------------|---|---|--|
| Demographics | Number of under-five children per quintile | 8,822,526, 7,737,789, 6,436,105, 5,806,958, 5,185,042 | Authors' calculation using national population size, median household size, and number of under-fives per households from [16] |
| Epidemiology | Cases of under-five malaria | 6,960,185, 6,468,963, 5,261,275, 3,361,056, 1,318,521 | Authors' calculation using prevalence data from [16] |
| | Cumulative annual incidence of uncomplicated under-five malaria (%) | 77.1, 81.9, 80.2, 57.0, 25.2 | Authors' calculation using treatment-seeking behavior and probability of disease progression to severe from [16] and [52] |
| | Cumulative annual incidence of severe under-five malaria (%) | 1.8, 1.7, 1.6, 0.8, 0.3 | Authors' calculation using treatment-seeking behavior and probability of disease progression to severe from [16] and [52] |
| | Treatment sought (%) | 67.8, 70.4, 72.4, 79.1, 85.2 | [16] |
| | Treatment coverage increase for 50% DMC subsidy (percentage point) | 2.5, 2, 1.5, 1, 0.5 | Authors' assumption |
| | Treatment coverage increase for full DMC subsidy (percentage point) | 5, 4, 3, 2, 1 | Authors' assumption |
| | Treatment coverage increase for full DMC + NMC + IC subsidy (percentage point) | 10, 8, 6, 4, 2 | Authors' assumption |
| | ACT used given treatment was sought (%) | 46.6, 51.5, 52.5, 53.1, 61 | [16] |
| | Complicated malaria as proportion of all cases (%) | 2 | Authors' estimate using [38] |
| | Uncomplicated malaria as a proportion of all cases (%) | 98 | Authors' estimate using [38] |
| Treatment | ACT efficacy (%) | 98.3 | [14] |
| | Adherence to treatment for uncomplicated cases (%) | 66, 71, 76, 81, 86 | Authors' assumption using overall estimate of adherence across all wealth indices from [40] |
| | Efficacy of ACT for uncomplicated cases given non-adherence as a proportion of theoretical efficacy (%) | 94.7 | [53] |
| | Non-ACT efficacy (%) | 63 | Authors' calculation using efficacy of chloroquine and all other non-ACTs from [6] |
| | Probability that untreated case progresses to severe (%) | 7 | Calibrated with low estimates from [52] |
| | Probability that treatment failure progresses to severe (%) | 2 | [54] |
| | CFR of untreated severe malaria (%) | 45 | Calibrated with low estimates from [51] |

| | | | |
|----------------------------|---|--------------------------------|---|
| | CFR of treated severe malaria (%) | 4.9 | [55] |
| | CFR of untreated uncomplicated malaria (%) | 0.1 | Authors' assumption based on [56] |
| Costing (2020 \$US) | Outpatient OOP direct medical costs per case, ACTs used | 7.98 | Authors' calculation using forthcoming data from multi-facility Duke costing study (see Supporting Information Section I, table 8) |
| | Outpatient OOP direct medical costs per case, non-ACTs used | 6.29 | Authors' calculation using [6] and forthcoming data from multi-facility Duke costing study (see Supporting Information Section I, tables 8 and 9) |
| | Outpatient OOP direct non-medical costs per case | 2.26 | Authors' calculation using forthcoming data from multi-facility Duke costing study (see Supporting Information Section I, table 10) |
| | Outpatient OOP indirect costs per case | 0.49, 0.78, 1.14, 1.70, 3.16 | Authors' calculation using data on daily consumption and days spent caregiving from [57] |
| | Inpatient OOP direct medical costs per case | 39.25 | Authors' calculation using forthcoming data from multi-facility Duke costing study (see Supporting Information Section I, table 8) |
| | Inpatient OOP direct non-medical costs per case | 4.16 | Authors' calculation using forthcoming data from multi-facility Duke costing study (see Supporting Information Section I, table 10) |
| | Inpatient OOP indirect costs per case | 2.98, 4.75, 6.91, 10.36, 19.26 | Authors' calculation using data on daily consumption and days spent caregiving from [57], [58] |
| | Outpatient cost of implementation per case, ACTs used | 10.50 | Authors' calculation using estimates of OOP expenditure as a percentage of total health expenditure in Nigeria [43] |
| | Outpatient cost of implementation per case, non-ACTs used | 8.28 | Authors' calculation using estimates of OOP expenditure as a percentage of total health expenditure in Nigeria [43] |
| | Inpatient cost of implementation per case | 51.65 | Authors' calculation using estimates of OOP expenditure as a percentage of total health expenditure in Nigeria [43] |
| | Nigeria GNI | 2030 | [59] |
| | Nigeria Gini Index | 35.1 | [60] |

151 **Model Flow**

152 TreeAge Pro Healthcare decision analysis software was used to create five decision trees,
 153 one for each wealth quintile (Q1-Q5, in ascending order of wealth). Each decision tree is identical
 154 in structure, but parameter values differ based on wealth quintile. The entry point for each tree is
 155 a case of under-five malaria. The total cases of under-five malaria per quintile were estimated
 156 using data from the 2019 World Malaria Report, the U.S. President's Malaria Initiative Nigeria
 157 Malaria Operational Plan for 2020, and the 2018 Nigeria DHS.[1,16,38]

158 The model's first chance node splits into clinically treated and untreated cases (**Fig 1A**).
 159 The probability that a case is clinically treated was proxied by the proportion of febrile under-fives

160 for whom treatment is sought, available from the 2018 Nigeria DHS. This approximation was
161 based on the fact that fever in under-fives is a relatively good indicator of malaria in endemic
162 countries.[39] Treated cases split into those treated with ACT and those treated with non-ACTs
163 (e.g., chloroquine, sulphadoxine-pyrimethamine), since ACT is the recommended standard first-
164 line treatment but not always used. Considering that the efficacy of ACT is highly dependent on
165 adherence to the prescribed treatment course, cases treated with ACT split into those both with
166 and without proper adherence.[40]

167 Both adherent and non-adherent cases were split into treatment success (defined as
168 adequate parasitological and clinical response—i.e., clearance of parasitemia) and treatment
169 failure. Cases not treated with ACT were split directly into treatment success and failure; the effect
170 of adherence on the efficacy of non-ACTs was not considered due to low overall treatment success
171 on account of growing antimalarial drug resistance.[41] Treatment success results in a green
172 terminal node representing survival (nodes 8, 16, and 24).

173 The orange nodes labeled Node 1, 9, 17, and 25 are associated with cases left untreated or
174 cases where treatment fails; accordingly, these nodes branch into trees that model the progression
175 of disease prognosis to severe (**Fig 1B**). The trees emanating from nodes 1, 9, 17 and 25 are
176 identical in structure but have parametric differences according to the specific therapeutic scenario,
177 discussed in more detail in Supporting Information Section II. Node 1 is displayed in **Fig 1B**,
178 initially splitting into cases that remain uncomplicated or progress to severe. Uncomplicated cases
179 split into survival and death, respectively resulting in terminal nodes 2 (green) and 3 (red). Severe
180 cases split into cases that are treated and untreated. It was assumed that the probability of seeking
181 treatment for cases that were initially untreated but progressed to severe was the same as the
182 probability of seeking treatment for uncomplicated cases (i.e., treatment of febrile under-fives).

183 Treated and untreated cases each split into survival and death, resulting in terminal nodes 4, 5, 6
184 and 7.

185 Using the TreeAge cost-effectiveness setting, cost and effectiveness values were assigned
186 at all terminal nodes. Terminal nodes resulting in survival were assigned an effectiveness value of
187 “1”, and terminal nodes resulting in death were assigned an effectiveness value of “0”. Cost values
188 were assigned according to the OOP cost incurred in each scenario in 2020 United States Dollars
189 (USD). Uncomplicated cases were assumed to incur outpatient costs and severe cases were
190 assumed to incur inpatient costs, an assumption commonly made in malaria modelling studies.[22]

191 For example, terminal node 24, which corresponds to uncomplicated cases treated with
192 ACT, was assigned a total case cost that included outpatient direct medical costs, non-medical
193 costs, and indirect costs (**Fig 1A**). Terminal node 2, corresponding to untreated uncomplicated
194 cases, was assigned no OOP cost (**Fig 1B**). Terminal node 4, corresponding to cases that were
195 initially untreated but treated upon progressing to severe, was assigned a total case cost that
196 included inpatient direct medical costs, non-medical costs, and indirect costs. Costing assignments
197 for all terminal nodes are discussed further in Supporting Information Section II. For the 50%
198 DMC intervention, direct medical costs were set at 50% of base case values. For the full DMC
199 intervention, direct medical costs were set at 0. For the full DMC + NMC + IC intervention, all
200 costs were set at 0.

201 Per quintile for each intervention scenario, annual OOP expenditure and surviving cases
202 were generated stochastically with Monte Carlo simulations using the TreeAge microsimulation
203 tool. The number of random walks simulated per quintile was the estimated number of malaria
204 cases per quintile. A total of about 23 million annual under-five cases were simulated, which is
205 corroborated by prior malaria modeling studies in Nigeria and data from the Institute of Health

206 Metrics and Evaluation (IHME) Global Burden of Disease database.[6,42] For intervention
207 scenarios, increased coverage was simulated by increasing the probability that a case was treated,
208 which is the parameter associated with the very first chance node (**Fig 1A**). OOP expenditure and
209 surviving cases per intervention scenario were compared against the outcomes of a base case
210 scenario in which treatment coverage was set as the status quo and no subsidy was applied to
211 treatment costs. Additionally, a comparison was made of the incremental OOP expenditure averted
212 between each intervention scenario.

213 Individual cases of catastrophic health expenditure (CHE) were estimated using a simple
214 disease model, described in Supporting Information Section IV.[31] Cases of CHE were calculated
215 using a threshold of 10% of annual per capita income, and CHE attributable to outpatient and
216 inpatient care were estimated separately.

217 **Cost of Implementation**

218 For each intervention, the government cost of implementation was estimated using the
219 same decision tree that was used to model deaths and OOP expenditure, but costing parameters
220 were changed to reflect government costs.[22] In Nigeria, OOP spending represents 76% of total
221 current health expenditure while government spending represents 24%.[43] The cost of
222 implementing each intervention we modelled was estimated accordingly.

223 For the full DMC intervention, where the direct medical costs of treatment are fully
224 subsidized, the government cost of implementation per case was estimated by dividing OOP direct
225 medical costs per case by 76%. For the 50% DMC intervention, the government cost of
226 implementation per case was set as 50% of this value. For the full DMC + NMC + IC intervention,
227 the government cost of implementation per case was set as the sum of total direct medical costs
228 per case (i.e., OOP cost divided by 76%) plus OOP non-medical and indirect costs per case.

229 Sensitivity analysis

230 Uncertainty in model outcomes was quantified using univariate sensitivity analysis. Each
231 model parameter was changed to reflect a high value and low value scenario (respectively 20%
232 higher and 20% lower than the base value). The relative impact of uncertainty in parameter values
233 was quantified by taking the percent difference between the model outcomes of high and low value
234 scenarios and base value scenarios. Uncertainty was estimated for total intervention effects across
235 all quintiles, averaged across all intervention scenarios unless otherwise noted in results.

236 RESULTS

237 Base case

238 In the base case scenario without intervention, the model estimated a total of 93,734 annual
239 under-five malaria deaths, 8,637 annual individual cases of CHE, and US\$205,221,385 in annual
240 OOP expenditure as a result of treating under-five malaria in Nigeria (**Table 2**). In this base case,
241 the poorest two quintiles accounted for 66% of mortality, 76% of CHE, and 53% of OOP
242 expenditure. Apart from quintile 1, cases of CHE were exclusively attributable to the cost of
243 inpatient hospitalization.

| Wealth quintile | Under-five deaths (thousands) | OOP expenditure (millions, US\$) | Cases of CHE (thousands) |
|-----------------|-------------------------------|----------------------------------|--------------------------|
| Q1 | 34.3 | 54.9 | 4.0 |
| Q2 | 27.9 | 54.2 | 2.6 |
| Q3 | 20.6 | 47.3 | 1.7 |
| Q4 | 8.9 | 33.3 | 0.4 |
| Q5 | 2.0 | 15.6 | 0 |
| Total | 93.7 | 205.2 | 8.6 |

250

251 **Deaths averted**

252 The 50% DMC, full DMC, and full DMC + NMC + IC subsidies respectively averted a
253 total of about 4,500, 9,300, and 19,000 under-five deaths (**Fig 2**). Across all intervention scenarios,
254 health benefits were concentrated among the poor, with the poorest two quintiles accounting for
255 72% of all deaths averted and the richest quintile accounting for 1% of all deaths averted on
256 average (Supporting Information Section VI, Fig 1).

257 **OOP expenditure averted**

258 The 50% DMC, full DMC, and full DMC + NMC + IC subsidies respectively averted a
259 total of US\$70.1 million, US\$142.1 million, and US\$205.2 million in OOP expenditure across all
260 quintiles (**Fig 3**). In all intervention scenarios, benefits were concentrated among the poor, with
261 the poorest two quintiles accounting for 55% and the richest quintile for accounting for 7% of total
262 OOP expenditure averted on average (Supporting Information Section VI, Fig 2).

263 In terms of OOP expenditure averted, the incremental benefits across interventions were
264 greater between the 50% DMC and the full DMC subsidies than between the full DMC and full
265 DMC + NMC + IC subsidies. On average across quintiles, the full DMC subsidy resulted in 202%
266 more OOP expenditure averted compared to the 50% DMC subsidy, while the full DMC + NMC
267 + IC subsidy resulted in 49% more OOP expenditure averted compared to the full DMC subsidy
268 (**Figs 4A, 4B**). The incremental economic benefits of the full DMC subsidy were marginally
269 greater for the poor than the wealthy (**Fig 4A**), while the incremental economic benefits of the full
270 DMC + NMC + IC subsidy were significantly greater for the wealthy than the poor (**Fig 4B**).

271 **CHE averted**

272 The 50% DMC, full DMC, and full DMC + NMC + IC subsidies respectively averted a
273 total of 7,202, 8,604, and 8,637 annual cases of individual CHE (**Fig 5**). Across all intervention

274 scenarios, the poorest two quintiles accounted for 74% of all cases of CHE averted on average
275 (Supporting Information Section VI, Fig 3), while quintile 5 experienced no CHE benefits. Only
276 quintiles 1 and 2 experienced incremental benefits between the 50% DMC and the full DMC
277 subsidies, with quintile 1 experiencing greater incremental benefits. Additionally, only quintile 1
278 experienced incremental benefits between the full DMC subsidy and the full DMC + NMC + IC
279 subsidy, which were marginal.

280 **Cost of implementation**

281 The 50% DMC, full DMC, and full DMC + NMC + IC subsidies would respectively cost
282 the government US\$90.5 million, US\$179.1 million, and US\$254.4 million to implement over one
283 year (**Table 3**). Across all intervention scenarios, the majority of expenditure would go toward
284 treatment coverage for the poorest Nigerians, with the poorest two quintiles accounting for 56%
285 of total intervention costs on average (Supporting Information Section VI, Fig 4).

| Table 3: Cost of implementation (in millions, US\$) | | | | | | |
|---|------|------|------|------|------|-------|
| Wealth quintile | Q1 | Q2 | Q3 | Q4 | Q5 | Total |
| 50% DMC subsidy | 25.7 | 24.7 | 20.4 | 13.9 | 5.8 | 90.5 |
| Full DMC subsidy | 51.1 | 48.9 | 40.3 | 27.4 | 11.5 | 179.1 |
| Full DMC + NMC + IC subsidy | 70.5 | 68.2 | 57.3 | 40.1 | 18.3 | 254.4 |

286 **Benefits per US\$1 million invested in each quintile**

287 Per US\$1 million invested in each quintile, deaths and cases of CHE averted were greatest
288 among the poor. For all interventions, investing US\$1 million into either of the bottom two
289 quintiles would avert more deaths and cases of CHE than investing broadly across all quintiles.
290 (**Tables 4**). Per US\$1 million invested in each quintile, OOP expenditure averted would be
291 relatively equitable in the intervention scenarios that do not subsidize nonmedical and indirect

292 costs. However, for subsidies of nonmedical and indirect costs, wealthy quintiles would avert more
 293 OOP expenditure than poor quintiles (**Table 4**).

Table 4: Benefits per US\$ 1 million invested in each quintile through targeted subsidies

| Scenario | 50% DMC subsidy | | | Full DMC Subsidy | | | Full DMC + NMC + IC Subsidy | | |
|-------------------------------|-----------------|----------------------|--------------------------------|------------------|----------------------|--------------------------------|-----------------------------|----------------------|--------------------------------|
| Wealth quintile | Deaths Averted | Cases of CHE Averted | OOP expenditure averted (\$US) | Deaths Averted | Cases of CHE Averted | OOP Expenditure Averted (\$US) | Deaths Averted | Cases of CHE Averted | OOP Expenditure Averted (\$US) |
| Q1 | 68 | 112 | 767,068 | 78 | 77 | 786,639 | 118 | 56 | 777,721 |
| Q2 | 55 | 91 | 773,742 | 56 | 53 | 792,114 | 88 | 38 | 794,950 |
| Q3 | 46 | 81 | 778,850 | 42 | 41 | 798,819 | 65 | 29 | 825,721 |
| Q4 | 26 | 29 | 780,029 | 28 | 15 | 798,075 | 28 | 10 | 829,994 |
| Q5 | 17 | 0 | 781,625 | 10 | 0 | 794,492 | 10 | 0 | 851,721 |
| All quintiles (broad subsidy) | 50 | 80 | 774,472 | 52 | 48 | 793,126 | 76 | 34 | 806,708 |

294 Sensitivity Analysis

295 When changed by 20%, the most impactful model parameters on all ECEA outcomes on
 296 average were (1) the total number of annual under-five malaria cases and (2) initial treatment
 297 coverage, with average effect sizes of 21% and 24%, respectively (Supporting Information Section
 298 VII, table 1). In addition, the number of under-five deaths averted was also particularly impacted
 299 by (1) the probability that an untreated case progresses to severe and (2) the case fatality rate of
 300 untreated severe cases (effect sizes of 19% and 17%, respectively). OOP expenditure averted was
 301 more impacted by uncertainty in outpatient costs than inpatient costs, and uncertainty in direct
 302 medical costs was more impactful than uncertainty in nonmedical and indirect costs (effect sizes
 303 of 5% and 1%, respectively for outpatient and inpatient direct medical costs). The most impactful
 304 parameter on cases of CHE averted was inpatient direct medical cost (effect size of 40%). The cost
 305 of implementation was substantially more impacted by uncertainty in the costs of outpatient care
 306 than inpatient care (effect sizes of 10% and 1%, respectively). A summary of sensitivity analysis
 307 results is reported in the Supporting Information Sections VII.

308 **DISCUSSION**

309 We used extended cost-effectiveness analysis (ECEA) to estimate the health and economic
310 effects of subsidizing case management of under-five malaria in Nigeria. Our model estimates
311 93,734 annual under-five malaria deaths in a baseline, non-intervention scenario, 66% of which
312 are attributable to the poorest 40% of children (**Table 2**). Estimated baseline mortality is
313 comparable to figures reported by the WHO Severe Malaria Observatory and the IHME Global
314 Burden of Disease database, which both report about 95,000 annual under-five malaria deaths in
315 Nigeria.[42,44] Our model also estimates that Nigerians spend over US\$200 million annually on
316 case management of under-five malaria and that 53% of this cost is incurred by the poorest 40%
317 of Nigerians. This is a sizeable proportion of the reported US\$700 million in annual OOP spending
318 on malaria treatment, prevention, and other costs across all ages.[1] Our model estimates that this
319 high OOP expenditure results in over 8,600 annual individual cases of catastrophic health
320 expenditure (CHE), 76% of which are concentrated among the poorest 40% of Nigerians (**Table**
321 **2**). These results emphasize the extent of child health inequity in Nigeria, stressing the need to
322 employ an equity-focused approach to health policymaking that targets the poorest and most
323 underserved populations rather than the mainstream, one-size-fits-all approach that may
324 inadvertently favor the wealthy.[26,29] This is especially important in light of recent plateaus in
325 donor funding of malaria control programs, which may limit the scale of government
326 interventions.[35,45]

327 Our analysis is one of the first ECEAs of under-five malaria and to our knowledge the first
328 to investigate how the effects of any health intervention in Nigeria would be distributed across
329 socioeconomic lines. A recent ECEA of malaria interventions in Ethiopia found that scaling up
330 coverage of ACTs would afford the greatest health benefits and financial risk protection relative

331 to scaling up use of indoor residual spray, insecticide-treated bed nets, and a hypothetical
332 vaccine.[22] Consistent with our own analysis, this study also found that the health and economic
333 benefits of a treatment subsidy would be concentrated among the poor. Another ECEA found that
334 compared to other interventions in Ethiopia, such as those addressing childhood diarrhea and
335 pneumonia, malaria interventions would see modest benefits, but this is likely due to the relatively
336 low malaria burden in Ethiopia.[46,47] Our analysis builds on the exiting body of ECEA evidence
337 for malaria interventions in Sub-Saharan Africa by investigating different financing strategies that
338 account for nonmedical and indirect costs and expanding geographic scope to Nigeria, the most
339 malaria-burdened country in the world.[1]

340 In our case management intervention scenarios, we found that larger subsidies would
341 generally result in greater health and economic benefits (**Figs 2,3,5**). The full DMC + NMC + IC
342 subsidy, which averted 76 deaths per US\$1 million invested broadly across all wealth groups,
343 resulted in substantially greater health benefits than the full DMC and 50% DMC subsidies, which
344 respectively averted 52 and 50 deaths per US\$1 million invested across all wealth groups (**Table**
345 **4**). We also found that across intervention scenarios, benefits would be concentrated among the
346 poor, with the poorest 40% of children accounting for 72% of deaths averted, 55% of OOP
347 expenditure averted, and 74% of all cases of CHE averted on average (Supporting Information
348 Section VI, Figs 1-3).

349 We found that targeted subsidies of the poor would avert significantly more deaths than
350 non-targeted subsidies applied broadly across all wealth groups. For example, in the full DMC +
351 NMC + IC scenario, US\$1 million invested into the poorest 20% of Nigerians would avert 118
352 deaths, while US\$1 million invested broadly across all groups would avert 76 deaths, and US\$1
353 million invested into the richest 20% would avert 10 deaths (**Table 4**). Additionally, we found that

354 while targeted subsidies of direct medical costs would result in relatively equitable OOP savings
355 across wealth groups, subsidies of nonmedical and indirect costs would result in relatively more
356 OOP savings for the wealthy (**Fig 4B, Table 4**). For example, in the full DMC + NMC + IC
357 scenario, the wealthiest 20% of Nigerians would save about US\$850,000 per US\$1 million
358 invested while the poorest 20% would save about US\$780,000 per US\$1 million invested (**Table**
359 **4**). This is likely because higher income individuals incur higher indirect costs on account of
360 productive time lost to caring for sick children—however, these costs are less likely to be
361 catastrophic with increasing wealth.[36] A full DMC + NMC + IC subsidy targeted towards the
362 poor would result in the greatest number of deaths averted and cases of CHE averted while averting
363 OOP expenditure most equitably.

364 While a full DMC + NMC + IC subsidy would avert US\$63.1 million more OOP
365 expenditure than a full DMC subsidy, we found almost no difference in incremental cases of CHE
366 averted between the two scenarios. Resultingly, a broad full DMC + NMC + IC subsidy would
367 avert 34 cases of CHE per US\$1 million invested, compared to 48 cases averted in the full DMC
368 scenario and 80 cases averted in the 50% DMC scenario (**Table 4**). This suggests that CHE related
369 to case management of under-five malaria is largely attributable to the direct medical cost of
370 treatment, which is supported by our sensitivity analysis (Supporting Information Section VII table
371 1). While non-medical and indirect costs may not be catastrophic, compensating caregivers for
372 these costs may still incentivize care-seeking because individuals in Nigeria often experience
373 multiple different health problems in a given year (acute respiratory infection, pneumonia,
374 HIV/AIDS, etc.), and the cumulative nonmedical and indirect costs could be catastrophic.[48]
375 Targeted subsidies of the poor would avert significantly more cases of CHE than broad subsidies;
376 in the full DMC + NMC + IC scenario, for example, investing \$1 million into the poorest 20% of

377 Nigerians would avert 56 cases of CHE, compared to 34 cases averted if invested broadly and 0
378 cases averted if invested into the richest 20% (**Table 4**).

379 Some limitations in our study should be considered when interpreting the results. First, our
380 decision tree model is static, which assumes that the case load of malaria would remain the same
381 across the duration of the intervention course.[49] This assumption does not mirror the realities of
382 transmissible diseases like malaria, but the dynamics of malarial transmission are unlikely to
383 change significantly within a year of implementation, which is the projected time frame of the
384 scenarios we modelled. Furthermore, effective treatment has been shown to interrupt malaria
385 transmission, so this policy could potentially move Nigeria closer to malaria elimination and lower
386 costs in future years.[50,51] Second, our model assumes that case management of uncomplicated
387 malaria incurs outpatient health facility costs, but uncomplicated malaria is often treated in
388 community settings in Nigeria.[16] The likely impact of this assumption is an overestimation of
389 total OOP expenditure averted and total cost of implementation. Estimates of total financial risk
390 protection, however, are relatively unaffected by this assumption because in our model, CHE is
391 most impacted by the cost of severe malaria cases requiring inpatient hospitalization (Supporting
392 Information Section VII, table 1). Third and most significantly, our methodology approximates
393 initial treatment coverage rates as care-seeking behavior for febrile under-fives, a common
394 assumption made in modelling studies of malaria-endemic countries.[22] However, the etiology
395 of under-five fever can also include infection with HIV/AIDS, acute respiratory infection, anemia
396 and pneumonia, so care-seeking for febrile under-fives may not reflect the true coverage rate for
397 malaria treatment.[48] Initial treatment coverage is one of the most influential variables in our
398 model for estimation of all ECEA outcomes (average effect size of 24% when changed by 20%),
399 so this is a key limitation (Supporting Information Section VII, table 1).

400 Under-five malaria in Nigeria remains one of the biggest challenges to global child health.
401 Stark health inequities between the rich and the poor necessitate the introduction of targeted
402 interventions that benefit the most vulnerable. Targeted subsidization of case management of
403 under-five malaria may be a pro-poor intervention that leads to significant reductions in national
404 under-five mortality and illness-related impoverishment, contributing progress to several of the
405 Sustainable Development Goals including reducing poverty (SDG 1), ensuring good health and
406 well-being at all ages (SDG 3), and reducing inequality within societies (SDG 10). This study
407 provides context for future research that may inform possible policy recommendations. For
408 example, while our study estimates the costs and benefits of subsidizing case management of
409 under-five malaria, a budget impact analysis should be done to determine whether Nigeria can
410 afford such a policy. Furthermore, if case management subsidies are introduced into Nigeria's
411 Basic Healthcare Provision Fund (BHCPF), an actuarial analysis should be done to understand
412 how the BHCPF would be impacted.

Acknowledgements

The authors would like to thank Ashwini Sunil Deshpande from the Duke Center for Policy Impact in Global Health for assistance in data extraction from the Nigeria Living Standard Survey, Gavin Yamey from the Duke Center for Policy Impact in Global Health for project support, and Megan Knauer from the Duke Margolis Center for Health Policy for assistance with the TreeAge Pro Healthcare software.

Funding

RD received funding from the Department of Science and Society at Duke University through the Huang Fellowship and the Duke-Margolis Center for Health Policy at Duke University to cover his time. RD also received funding for TreeAge software from North Carolina State University through the George T. Barthalmus Research Award. WM and OO were funded through Duke CPIGH's 4D transitions study in Nigeria supported by the Bill and Melinda Gates Foundation (OPP1199624) and the Partnership for Maternal Newborn and Child Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests

The authors have no competing interests to declare.

Figures 1-5

Fig 1A




Fig 1B




Fig 1A: Parent decision tree used to model annual under-five malaria deaths and OOP expenditure in Nigeria. The entry point in the model is a case of under-five malaria. Identical trees were used for each wealth quintile (Q1-Q5) but with different parameters (costs, mortality, and case load). Green terminal nodes are associated with survival. Orange nodes feed into subtrees representing cases that are either untreated (Node 1) or where treatment failure occurs (Nodes 9, 17, and 25). **Fig 1B:** Subtree modelling under-five malaria cases that are either untreated or where treatment failure occurs, representing cases that may progress to severe. Green terminal nodes are associated with survival and red terminal nodes are associated with death.




Fig 2: Annual under-five malaria deaths averted by wealth quintile (Q1-Q5) in Nigeria by implementing three different interventions. Deaths averted are concentrated among the poor.




Fig 3: Annual under-five malaria related OOP expenditure averted by wealth quintile (Q1-Q5) in Nigeria by implementing three different interventions. OOP expenditure averted is concentrated among the poor.

Fig 4A Percent Difference in OOP Expenditure Averted Between 50% DMC Subsidy and Full DMC Subsidy, by Quintile (1-5)




Fig 4B Percent Difference in OOP Expenditure Averted Between Full DMC Subsidy and Full DMC + NMC + IC subsidy, by Quintile (1-5)




Fig 4A: Incremental benefits in OOP expenditure averted between a 50% DMC subsidy and full DMC subsidy by wealth quintile (Q1-Q5). Incremental benefits marginally decrease with wealth.

Fig 4B: Incremental benefits in OOP expenditure averted between a full DMC subsidy and full DMC + NMC + IC subsidy by wealth quintile (Q1-Q5). Incremental benefits increase with wealth.




Fig 5: Annual under-five malaria related CHE averted by wealth quintile (Q1-Q5) in Nigeria by implementing three different interventions. CHE averted is concentrated among the poor.

References

1. World malaria report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
2. Global Technical Strategy for Malaria 2016–2030. Geneva: World Health Organization; 2016.
3. World malaria report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
4. Fact Sheet about Malaria. *World Health Organization*, World Health Organization, 2020, www.who.int/news-room/fact-sheets/detail/malaria. Accessed Dec 2020.
5. Onwujekwe, O, Uguru, N, Etiaba, E, *et al.* The economic burden of malaria on households and the health system in Enugu State southeast Nigeria. *PloS One* 2013;8: e78362. <https://doi.org/10.1371/journal.pone.0078362>
6. Beargie SM, Higgins CR, Evans DR *et al.* The economic impact of substandard and falsified antimalarial medications in Nigeria. *PLoS One* 2019;14(8):e0217910. <https://doi.org/10.1371/journal.pone.0217910>
7. Edelu B O, Ndu I K, Igbokwe O *et al.* Severe falciparum malaria in children in Enugu, South East Nigeria. *Niger J Clin Pract* 2018;21:1349-55.
8. United States Embassy in Nigeria. Nigeria Malaria Fact Sheet; 2011. Retrieved from <https://photos.state.gov/libraries/nigeria/231771/Public/December-MalariaFactSheet2.pdf>. Accessed Dec 2020.
9. United States Embassy in Nigeria, Nigeria Malaria Fact Sheet; 2013. Retrieved from <http://photos.state.gov/libraries/nigeria/231771/Public/December-MalariaFactSheet2.pdf>. Accessed Dec 2020.
10. Adewemimo A, Kalter HD, Perin J *et al.* Direct estimates of cause-specific mortality fractions and rates of under-five deaths in the northern and southern regions of Nigeria by verbal autopsy interview. *PLoS One* 2017;12(5): e0178129. <https://doi.org/10.1371/journal.pone.0178129>
11. Uneke, C, Sombie, I, Uro-Chukwu, H *et al.* Developing equity-focused interventions for maternal and child health in Nigeria: an evidence synthesis for policy, based on equitable impact sensitive tool (EQUIST). *Pan Afr Med J* 2019; 34:158. doi:10.11604/pamj.2019.34.158.16622
12. Ezenduka, C, Falleiros, D, & Godman, B. Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications. *Pharmacoecon Open*, 2013;1(3), 185–194. <https://doi.org/10.1007/s41669-017-0021-8>
13. Bhutta Z, Black R. Global maternal, newborn, and child health-so near and yet so far. *N Engl J Med* 2013;369(23):2226-2235.
14. Thwing, J, Eisele, T, Steketee, R. Protective efficacy of malaria case management for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. *BMC Public Health*, 2011;11(3).doi:10.1186/1471-2458-11-S3-S14.
15. O'Connell, K, Gatakaa, H, Poyer, S *et al.* Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in

- six malaria-endemic countries. *Malar J* 2010;10, 326. <https://doi.org/10.1186/1475-2875-10-326>
16. National Population Commission - NPC/Nigeria and ICF. 2019. Nigeria Demographic and Health Survey 2018. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF.
 17. Kumar, S, Kumar, N, & Vivekadhish, S. Millennium Development Goals (MDGs) to Sustainable Development Goals (SDGs): Addressing Unfinished Agenda and Strengthening Sustainable Development and Partnership. *Indian J Community Med* 2016; 41(1),1–4. <https://doi.org/10.4103/0970-0218.170955>
 18. Onwujekwe O, Obi F, Ichoku H, Ezumah N *et al.* Assessment of a free maternal and child health program and the prospects for program re-activation and scale-up using a new health fund in Nigeria. *Niger J Clin Pract* 2019;22:1516-29
 19. Ogbuabor, D & Onwujekwe, O. Implementation of free maternal and child healthcare policies: assessment of influence of context and institutional capacity of health facilities in South-east Nigeria. *Glob Health Action* 2018;11(1), 1535031. <https://doi.org/10.1080/16549716.2018.1535031>
 20. Onwujekwe O, Hanson K, Uzochukwu B *et al.* Are malaria treatment expenditures catastrophic to different socio-economic and geographic groups and how do they cope with payment? A study in southeast Nigeria. *Trop Med Int Health* 2010 Jan;15(1):18-25. doi: 10.1111/j.1365-3156.2009.02418.x.
 21. Acharya, S, Lin, V, & Dhingra, N. The role of health in achieving the sustainable development goals. *Bull World Health Organ* 2018;96(9),591–591A. <https://doi.org/10.2471/BLT.18.221432>
 22. Assebe, L, Kwete, XJ, Wang, D *et al.* Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis. *Malar J* 2020;19,41.<https://doi.org/10.1186/s12936-020-3103-5>
 23. Verguet S, Woldemariam AT, Durrett WN *et al.* Is the sustainable development goal target for financial risk protection in health realistic? *BMJ Glob Health* 2017;2(3):e000216.doi:10.1136/bmjgh-2016-000216
 24. WHO. (n.d.). Sustainable Development Goals. Retrieved December 14, 2020, from <https://www.who.int/health-topics/sustainable-development-goals> Accessed Dec 2020.
 25. Abihiro, GA & De Allegri, M. Universal health coverage from multiple perspectives: a synthesis of conceptual literature and global debates. *BMC Int Health Hum Rights* 2015;15,17.<https://doi.org/10.1186/s12914-015-0056-9>
 26. White, MT, Conteh, L, Cibulskis, R *et al.* Costs and cost-effectiveness of malaria control interventions - a systematic review. *Malar J* 2010;10,337. <https://doi.org/10.1186/1475-2875-10-337>
 27. UNICEF. Narrowing the Gaps: The power of investing in the poorest children. 2017. Retrieved from https://www.equist.info/files/general_files/GLB_3418glb-9355narrowing-the-gaps-2017.pdf. Accessed Nov 2020.
 28. Waters, D, Theodoratou, E, Campbell, H *et al.* Optimizing community case management strategies to achieve equitable reduction of childhood pneumonia mortality: An application of Equitable Impact Sensitive Tool (EQUIST) in five low- and middle-income countries. *J Glob Health* 2012;2(2),020402. <https://doi.org/10.7189/jogh.02.020402>

29. Chao, F, You, D, Pedersen, J *et al.* National and regional under-5 morality rate by economic status for low-income and middle-income countries: a systematic assessment. *Lancet* 2018;(6),e535-547.
30. Carrera C, Azrack A, Begkoyian G *et al.* The comparative cost-effectiveness of an equity-focused approach to child survival, health, and nutrition: a modelling approach. *Lancet* 2012;380(9850):1341-1351.
31. Verguet, S, Kim, J, Jamison, D. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. *Pharmacoeconomics* 2016;34(913-923).doi:10.1007/s40273-016-0414-z
32. Scott, N, Hussain, SA, Martin-Hughes, R *et al.* Maximizing the impact of malaria funding through allocative efficiency: using the right interventions in the right locations. *Malar J* 2017;16,368. <https://doi.org/10.1186/s12936-017-2019-1>
33. Houben CH, Fleischmann H, Gückel M. Malaria prevalence in north-eastern Nigeria: a cross-sectional study. *Asian Pac J Trop Med* 2013;6(11):865-868. DOI: 10.1016/s1995-7645(13)60154-6.
34. Hailu, A, Lindtjørn, B, Deressa, W *et al.* Economic burden of malaria and predictors of cost variability to rural households in south-central Ethiopia. *PloS One* 2017;12(10), e0185315. <https://doi.org/10.1371/journal.pone.0185315>
35. Arrow KJ, Panosian C, Gelband H, editors. The Human and Economic Burden of Malaria. In: Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington (DC): National Academies Press (US); 2004. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK215634/>
36. El-Houderi, A, Constantin, J, Castelnuovo *et al.* Economic and Resource Use Associated With Management of Malaria in Children Aged <5 Years in Sub-Saharan Africa: A Systematic Literature Review. *MDM Policy Pract* 2019. DOI:10.1177/2381468319893986
37. Cohen, JL, Yadav, P, Moucheraud, C *et al.* Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania. *PloS One* 2019;8(7), e70713. <https://doi.org/10.1371/journal.pone.0070713>
38. U.S. President's Malaria Initiative Nigeria Malaria Operational Plan FY 2020. Retrieved from (www.pmi.gov). Accessed Dec 2020.
39. Stresman, G, Sepúlveda, N, Fornace, K, *et al.* Association between the proportion of Plasmodium falciparum and Plasmodium vivax infections detected by passive surveillance and the magnitude of the asymptomatic reservoir in the community: a pooled analysis of paired health facility and community data. *Lancet Infect Dis* 2020;20(8), 953–963. [https://doi.org/10.1016/S1473-3099\(20\)30059-1](https://doi.org/10.1016/S1473-3099(20)30059-1)
40. Yakasai A, Hamza M, Dalhat M *et al.* Adherence to Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria: A Systematic Review and Meta-Analysis. *J Trop Med* 2015;2015. <https://doi.org/10.1155/2015/189232>

41. Antony, HA & Parija, SC. Antimalarial drug resistance: An overview. *Trop Parasitol* 2016;6(1),30–41. <https://doi.org/10.4103/2229-5070.175081>
42. IHME GBD Results Tool. (2019). Retrieved from <http://ghdx.healthdata.org/gbd-results-tool>. Accessed Nov 2020.
43. Aregbeshola, BS & Khan, S.M. Out-of-pocket health-care spending and its determinants among households in Nigeria: a national study. *J Public Health (Berl.)* 2020. <https://doi.org/10.1007/s10389-020-01199-x>
44. Nigeria severe malaria facts. (2020). Retrieved from <https://www.severemalaria.org/countries/nigeria>. Accessed Nov 2020.
45. Korenromp, E, Mahiané, G, Hamilton, M *et al.* Malaria intervention scale-up in Africa: effectiveness predictions for health programme planning tools, based on dynamic transmission modelling. *Malar J* 2016;15,417. <https://doi.org/10.1186/s12936-016-1461-9>
46. Pecenka CJ, Johansson KA, Memirie ST *et al.* Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia. *BMJ Open* 2015;5:e006402.
47. Verguet S, Olson ZD, Babigumira JB *et al.* Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. *Lancet Glob Health* 2015;3:e288–96.
48. Enya, V, Idika, N, Mafe, AG *et al.* Aetiology of fever among under fives in Lagos, Nigeria. *BMC Infectious Diseases*, 2014;14(Suppl 2),P42. <https://doi.org/10.1186/1471-2334-14-S2-P42>
49. Lugnér AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. *Health Econ* 2010;19(5):518-31. doi:10.1002/hec.1485. PMID: 19382106.
50. White NJ. The role of anti-malarial drugs in eliminating malaria. *Malar J* 2008;11;7 Suppl 1(Suppl 1):S8. doi:10.1186/1475-2875-7-S1-S8.
51. Guidelines for the Treatment of Malaria. 3rd edition. Geneva: World Health Organization; 2015. Annex 2, Malaria transmission and antimalarial medicines. Retrieved from: <https://www.ncbi.nlm.nih.gov/books/NBK294437/>
52. Lubell, Y, Staedke, SG, Greenwood, BM *et al.* Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. *PloS one* 2011;6(2),e17439. <https://doi.org/10.1371/journal.pone.0017439>
53. Challenger, JD, Bruxvoort, K, Ghani, AC *et al.* Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling. *Nat Commun* 2017;8,1373.
54. Lubell Y, Dondorp A, Guerin PJ, *et al.* Artemisinin resistance—modelling the potential human and economic costs. *Malar J* 2014;13:452. doi:10.1186/1475-2875-13-452
55. Graham, H, Bakare, AA, Ayede, AI *et al.* Diagnosis of pneumonia and malaria in Nigerian hospitals: A prospective cohort study. *Pediatr Pulmonol* 2020;55(S1). doi:10.1002/ppul.24691
56. Olliaro, P. Mortality Associated with Severe *Plasmodium falciparum* Malaria Increases with Age, *Clinical Infect Dis* 2008;47(2) 158-160.
57. Nigeria National Bureau of Statistics (NBS). General Household Survey, Panel 2015-2016, Wave 3.

58. Hennessee, I, Chinkhumba, J, Briggs-Hagen, M *et al.* Household costs among patients hospitalized with malaria: evidence from a national survey in Malawi, 2012. *Malar J* 2017;16,395.<https://doi.org/10.1186/s12936-017-2038-y>
59. The World Bank. (2020). Gini index (World Bank estimate). Retrieved from <https://data.worldbank.org/indicator/SI.POV.GINI> Accessed Dec 2020.
60. The World Bank. Nigeria. (2020). Retrieved from <https://data.worldbank.org/country/NG> Accessed Dec 2020.